A detailed history of Umb Bank, N.A. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Umb Bank, N.A. holds 5,194 shares of VRTX stock, worth $2.61 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
5,194
Previous 5,226 0.61%
Holding current value
$2.61 Million
Previous $2.45 Million 1.39%
% of portfolio
0.04%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

SELL
$460.0 - $505.78 $14,720 - $16,184
-32 Reduced 0.61%
5,194 $2.42 Million
Q2 2024

Jul 29, 2024

SELL
$392.81 - $485.53 $458,016 - $566,127
-1,166 Reduced 18.24%
5,226 $2.45 Million
Q1 2024

Apr 26, 2024

SELL
$407.69 - $446.08 $12.3 Million - $13.4 Million
-30,103 Reduced 82.49%
6,392 $2.67 Million
Q4 2023

Jan 23, 2024

SELL
$343.0 - $410.68 $723,387 - $866,124
-2,109 Reduced 5.46%
36,495 $14.8 Million
Q3 2023

Oct 18, 2023

SELL
$338.18 - $362.46 $1.28 Million - $1.38 Million
-3,798 Reduced 8.96%
38,604 $13.4 Million
Q2 2023

Jul 25, 2023

BUY
$314.42 - $351.91 $94,326 - $105,573
300 Added 0.71%
42,402 $14.9 Million
Q1 2023

Apr 11, 2023

SELL
$283.23 - $323.1 $369,898 - $421,968
-1,306 Reduced 3.01%
42,102 $13.3 Million
Q4 2022

Jan 10, 2023

BUY
$285.76 - $321.48 $297,761 - $334,982
1,042 Added 2.46%
43,408 $12.5 Million
Q3 2022

Oct 13, 2022

BUY
$273.83 - $305.53 $5.85 Million - $6.53 Million
21,362 Added 101.7%
42,366 $12.3 Million
Q2 2022

Jul 20, 2022

BUY
$234.96 - $292.55 $4.89 Million - $6.09 Million
20,829 Added 11902.29%
21,004 $5.92 Million
Q1 2022

Apr 22, 2022

BUY
$221.42 - $260.97 $221 - $260
1 Added 0.57%
175 $46,000
Q4 2021

Feb 09, 2022

BUY
$177.01 - $223.45 $30,799 - $38,880
174 New
174 $38,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Umb Bank, N.A. Portfolio

Follow Umb Bank, N.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Umb Bank, N.A., based on Form 13F filings with the SEC.

News

Stay updated on Umb Bank, N.A. with notifications on news.